Shares of Pluristem Therapeutics Inc. (PSTI) are surging over 33% in pre-market today, after the company announced preliminary data from its compassionate use program, treating seven patients suffering from acute respiratory failure and inflammatory complications associated with COVID-19 with Pluristem's PLX cells, in three medical centers in Israel.
from RTT - Before the Bell https://ift.tt/2USYlA9
via IFTTT
No comments:
Post a Comment